.
BioEnterprise

Cleveland HeartLab

Cleveland HeartLab is involved in the discovery and validation of molecular biomarkers and their development into products that aid in the diagnosis and treatment of a variety of diseases. The initial focus is on Myeloperoxidase (MPO), a diagnostic marker of cardiovascular risk, and the company has received 510(k) clearance to market its first biomarker, CardioMPO.

Funding

HealthCare Ventures, Excel Venture Management, Glengary Ventures, Zapis Capital, Second Generation, Mutual Capital Partners, Bratenahl Capital Partners, Merck Global Health Innovation, Angel Investor

Stage

Commercial